Celgene Corp. (NASDAQ:CELG)’s share price traded up 2.4% during mid-day trading on Thursday . The stock traded as high as $107.36 and last traded at $107.17, with a volume of 3,780,151 shares changing hands. The stock had previously closed at $104.62.

Several equities analysts recently issued reports on the stock. Piper Jaffray Cos. reissued a “buy” rating on shares of Celgene Corp. in a research note on Thursday, April 28th. Credit Suisse Group AG reissued an “outperform” rating and set a $140.00 price objective on shares of Celgene Corp. in a research note on Thursday, May 5th. SunTrust Banks Inc. reissued a “buy” rating and set a $147.00 price objective (up previously from $145.00) on shares of Celgene Corp. in a research note on Thursday, April 28th. Zacks Investment Research downgraded shares of Celgene Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, May 3rd. Finally, Vetr downgraded shares of Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $120.74 price objective on the stock. in a research note on Thursday, June 2nd. Six research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $138.51.

The stock has a market cap of $83.23 billion and a PE ratio of 52.26. The firm’s 50 day moving average is $102.14 and its 200 day moving average is $103.21.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.29 by $0.03. During the same quarter in the previous year, the firm posted $1.07 earnings per share. The firm earned $2.51 billion during the quarter, compared to analyst estimates of $2.59 billion. Celgene Corp.’s quarterly revenue was up 20.7% compared to the same quarter last year. Analysts predict that Celgene Corp. will post $5.70 earnings per share for the current year.

In related news, insider Robert J. Hugin sold 75,000 shares of the business’s stock in a transaction on Monday, June 20th. The shares were sold at an average price of $100.16, for a total transaction of $7,512,000.00. Following the transaction, the insider now owns 1,122,201 shares of the company’s stock, valued at $112,399,652.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Other institutional investors recently made changes to their positions in the company. Synovus Financial Corp raised its position in shares of Celgene Corp. by 16.6% in the fourth quarter. Synovus Financial Corp now owns 8,571 shares of the biopharmaceutical company’s stock worth $1,027,000 after buying an additional 1,222 shares during the period. WMS Partners LLC raised its position in shares of Celgene Corp. by 20.9% in the fourth quarter. WMS Partners LLC now owns 8,669 shares of the biopharmaceutical company’s stock worth $1,038,000 after buying an additional 1,500 shares during the period. Genesee Valley Trust Co. raised its position in shares of Celgene Corp. by 4.2% in the fourth quarter. Genesee Valley Trust Co. now owns 8,820 shares of the biopharmaceutical company’s stock worth $1,056,000 after buying an additional 359 shares during the period. Investment Management of Virginia LLC raised its position in shares of Celgene Corp. by 63.0% in the fourth quarter. Investment Management of Virginia LLC now owns 9,043 shares of the biopharmaceutical company’s stock worth $1,083,000 after buying an additional 3,495 shares during the period. Finally, NBT Bank N A NY raised its position in shares of Celgene Corp. by 0.3% in the fourth quarter. NBT Bank N A NY now owns 9,248 shares of the biopharmaceutical company’s stock worth $1,107,000 after buying an additional 30 shares during the period.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.